Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 16536900)

1.

Novel depots of buprenorphine have a long-acting effect for the management of physical dependence to morphine.

Liu KS, Kao CH, Liu SY, Sung KC, Kuei CH, Wang JJ.

J Pharm Pharmacol. 2006 Mar;58(3):337-44.

PMID:
16536900
2.

Multiple mechanisms underlying the long duration of action of thienorphine, a novel partial opioid agonist for the treatment of addiction.

Yu G, Li SH, Cui MX, Yan LD, Yong Z, Zhou PL, Su RB, Gong ZH.

CNS Neurosci Ther. 2014 Mar;20(3):282-8. doi: 10.1111/cns.12210. Epub 2013 Dec 16.

PMID:
24330593
3.

Case report of substance dependence with buprenorphine and mephentermine.

Mendhekar DN, Sharma H, Dali JS.

Indian J Psychiatry. 1999 Apr;41(2):160-2.

4.

Commentary on Kraft et al. (2011): Treatment of neonatal abstinence syndrome - morphine, buprenorphine and beyond.

Jones HE.

Addiction. 2011 Mar;106(3):581-2. doi: 10.1111/j.1360-0443.2010.03236.x. No abstract available.

PMID:
21299671
5.

The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.

Mammen K, Bell J.

Expert Opin Pharmacother. 2009 Oct;10(15):2537-44. doi: 10.1517/14656560903213405. Review.

PMID:
19708849
6.
7.

Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy.

Messinis L, Lyros E, Andrian V, Katsakiori P, Panagis G, Georgiou V, Papathanasopoulos P.

Hum Psychopharmacol. 2009 Oct;24(7):524-31. doi: 10.1002/hup.1050.

PMID:
19650155
8.

Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection.

Wang JJ, Liu KS, Sung KC, Tsai CY, Fang JY.

Eur J Pharm Sci. 2009 Sep 10;38(2):138-46. doi: 10.1016/j.ejps.2009.06.008. Epub 2009 Jul 8.

PMID:
19591929
9.

Buprenorphine for opioid dependence.

Milne M, Crouch BI, Caravati EM.

J Pain Palliat Care Pharmacother. 2009;23(2):153-5. doi: 10.1080/15360280902900869. Review.

PMID:
19492216
10.

Evaluation of the antidiarrhoeal effect of Sanseviera liberica Gerome & Labroy (Agavaceae) root extract.

Adeyemi OO, Akindele AJ, Ogunleye EA.

J Ethnopharmacol. 2009 Jun 25;123(3):459-63. doi: 10.1016/j.jep.2009.03.023. Epub 2009 Mar 26.

PMID:
19481383
11.

Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence.

White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, Beebe KL.

Drug Alcohol Depend. 2009 Jul 1;103(1-2):37-43. doi: 10.1016/j.drugalcdep.2009.03.008. Epub 2009 Apr 28.

PMID:
19403243
12.

Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.

Reece AS.

J Subst Abuse Treat. 2009 Oct;37(3):256-65. doi: 10.1016/j.jsat.2009.03.008. Epub 2009 Apr 25.

PMID:
19394789
13.

Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.

Orman JS, Keating GM.

Drugs. 2009;69(5):577-607. doi: 10.2165/00003495-200969050-00006. Review.

PMID:
19368419
14.

Pediatric palliative care: use of opioids for the management of pain.

Zernikow B, Michel E, Craig F, Anderson BJ.

Paediatr Drugs. 2009;11(2):129-51. doi: 10.2165/00148581-200911020-00004. Review.

PMID:
19301934
15.

Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects.

De S, Jain R, Ray R, Dhawan A, Varghese ST.

Indian J Physiol Pharmacol. 2008 Jan-Mar;52(1):53-63.

PMID:
18831352
16.

A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone).

Simojoki K, Vorma H, Alho H.

Subst Abuse Treat Prev Policy. 2008 Jun 17;3:16. doi: 10.1186/1747-597X-3-16.

17.

Effects of the fruit essential oil of Cuminum cyminum Linn. (Apiaceae) on acquisition and expression of morphine tolerance and dependence in mice.

Haghparast A, Shams J, Khatibi A, Alizadeh AM, Kamalinejad M.

Neurosci Lett. 2008 Aug 1;440(2):134-9. doi: 10.1016/j.neulet.2008.05.060. Epub 2008 May 22.

PMID:
18550281
18.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
19.

Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management.

Roux P, Villes V, Blanche J, Bry D, Spire B, Feroni I, Carrieri MP.

Drug Alcohol Depend. 2008 Sep 1;97(1-2):105-13. doi: 10.1016/j.drugalcdep.2008.03.025. Epub 2008 May 13.

PMID:
18479840
20.

Effects of intragastric agmatine on morphine-induced physiological dependence in beagle dogs and rhesus monkeys.

Su RB, Lu XQ, Huang Y, Liu Y, Gong ZH, Wei XL, Wu N, Li J.

Eur J Pharmacol. 2008 Jun 10;587(1-3):155-62. doi: 10.1016/j.ejphar.2008.03.022. Epub 2008 Mar 29.

PMID:
18455724
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk